Innovation Articles

1. Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries 11/11/2026

   David Adler, MD, Ph.D., MBA, explains how earlier collaboration between academic and pharma researchers can strengthen oncology discoveries that lead to clinical trials.

2. Targeting MSH3 To Slow Huntington's Disease Progression 11/10/2026

   A study published in Nature Communications integrates a predictive computational model of Huntington’s disease built on human data, designed to reduce MSH3 expression in striatal and cortical neurons 

3. How Peptides Are Expanding The Possibilities Of Drug Discovery 11/9/2026

   GLP-1 therapies demonstrate the impact peptide medicines have. The opportunity ahead is to extend that impact across a much broader range of biology and achieve new ways to intervene.

4. Built To Avoid Risk: How Industry Norms Stall Drug Discovery 10/28/2026

   At Discovery & Development US 2026 in San Diego, discovery leaders named the industry norms they would change.

5. Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield? 10/22/2026

   Backed by $93 million, CoRegen is bringing a novel Treg-engineering strategy into the clinic to test whether CRG-150 can dismantle solid tumors’ immune defenses.

6. Discovery & Development US 2026 - Key Notes From San Diego 10/19/2026

   Key takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs.

7. Finding The Therapeutic Window: Using Single-Cell Biology To Build More Selective T-Cell Engagers 10/6/2026

   Cyril Konto, MD, discusses Shennon Biotechnologies programs in small cell lung cancer, ovarian cancer, and hepatocellular carcinoma, and spans antibody and TCR-based T-cell engagers.

8. Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies 9/3/2026

   Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

9. The Future Of Cancer Drug Discovery Is Targeted Immune Activation 9/2/2026

   Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.

10. A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials 9/1/2026

    CSB-001, Claris Bio’s eye drop for limbal stem cell deficiency, could offer a non-surgical way to improve vision, slow vision loss, and reshape LSCD care.